$2.67 Million in Sales Expected for Mediwound Ltd (NASDAQ:MDWD) This Quarter

Wall Street analysts expect that Mediwound Ltd (NASDAQ:MDWD) will post sales of $2.67 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Mediwound’s earnings, with the highest sales estimate coming in at $4.10 million and the lowest estimate coming in at $1.20 million. Mediwound posted sales of $860,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 210.5%. The firm is expected to issue its next earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Mediwound will report full year sales of $17.00 million for the current year, with estimates ranging from $8.80 million to $26.50 million. For the next fiscal year, analysts anticipate that the company will post sales of $12.12 million, with estimates ranging from $5.89 million to $18.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Mediwound.

Mediwound (NASDAQ:MDWD) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $7.03 million. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%.

Several equities research analysts have recently commented on MDWD shares. Oppenheimer decreased their target price on shares of Mediwound from $15.00 to $7.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Zacks Investment Research raised shares of Mediwound from a “hold” rating to a “buy” rating and set a $3.25 target price for the company in a research report on Saturday. HC Wainwright assumed coverage on shares of Mediwound in a research report on Monday, August 5th. They set a “buy” rating and a $5.50 target price for the company. Finally, ValuEngine upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.

A number of institutional investors have recently added to or reduced their stakes in MDWD. Delek Group Ltd. purchased a new position in Mediwound during the first quarter worth about $141,000. Marshall Wace LLP purchased a new position in Mediwound during the first quarter worth about $93,000. ARK Investment Management LLC purchased a new position in Mediwound during the second quarter worth about $325,000. Oppenheimer & Co. Inc. boosted its holdings in Mediwound by 33.5% during the second quarter. Oppenheimer & Co. Inc. now owns 43,800 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Sargent Investment Group LLC boosted its holdings in Mediwound by 114.8% during the second quarter. Sargent Investment Group LLC now owns 29,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 15,500 shares during the last quarter. Institutional investors and hedge funds own 28.75% of the company’s stock.

Shares of NASDAQ:MDWD traded down $0.01 during midday trading on Friday, hitting $2.98. 22,612 shares of the company’s stock were exchanged, compared to its average volume of 28,180. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.13 and a quick ratio of 3.99. The stock has a 50 day moving average price of $3.13 and a 200-day moving average price of $3.79. The company has a market cap of $79.91 million, a PE ratio of -6.08 and a beta of 0.48. Mediwound has a 12 month low of $2.55 and a 12 month high of $6.19.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Recommended Story: How to start trading in the forex market?

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit